This is a StreetInsider.com Premium Only Page

(PRDS) – StreetInsider.com Reports

Jul 18, 2023 03:43 AM JMP Securities Downgrades Pardes Biosciences (PRDS) to Market Perform

Jul 17, 2023 07:00 AM Pardes Biosciences (PRDS) to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

Jul 17, 2023 06:56 AM Pardes Biosciences (PRDS) Halted, News Pending

Apr 4, 2023 07:47 AM Jefferies Downgrades Pardes Biosciences (PRDS) to Hold

Apr 4, 2023 03:27 AM SVB Leerink Downgrades Pardes Biosciences (PRDS) to Market Perform

Apr 3, 2023 08:28 AM Pardes Biosciences (PRDS) to Resume Trading at 8:30 a.m.

Apr 3, 2023 08:02 AM Pardes Biosciences (PRDS) Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Apr 3, 2023 07:56 AM Pardes Biosciences (PRDS) Halted, News Pending

Jan 12, 2023 06:38 AM Pardes Biosciences (PRDS) Files $200M Mixed Shelf

Dec 13, 2022 03:16 AM JMP Securities Starts Pardes Biosciences (PRDS) at Market Outperform

Dec 5, 2022 05:48 PM After-hours movers: GitLab jumps on earnings, Textron on Army copter win

Dec 5, 2022 04:42 PM Insider Buy: Pardes Biosciences (PRDS) Sees Buying from CEO and 10% Owner

Sep 14, 2022 08:03 AM Pardes Biosciences (PRDS) Appoints Laurie Smaldone Alsup and John C. Pottage to its Board

Mar 15, 2022 07:23 AM SVB Leerink Starts Pardes Biosciences (PRDS) at Outperform

Mar 2, 2022 04:31 PM Pardes Biosciences (PRDS) Appoints Thomas G. Wiggans to CEO and Chairman of the Board

Feb 14, 2022 07:30 AM Pardes Biosciences (PRDS) Reports Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial

Feb 3, 2022 07:01 AM Pardes Biosciences (PRDS) Granted FDA Clearance of IND Application for PBI-0451

Jan 28, 2022 04:48 PM Pardes Biosciences (PRDS) Announces 39.76M Share Offering by Selling Stockholders

Jan 18, 2022 07:43 AM Jefferies Starts Pardes Biosciences (PRDS) at Buy